Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

solid tumors in conjunction with standard antineoplastic therapy; prostate cancer should have progressed after treatment with at least one hormonal therapy.

Zometa is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa. Hypersensitivity reactions, including rare cases of urticaria and angioedema and very rare cases of anaphylactic reaction/shock, have been reported.

Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of Zometa should not exceed 4 mg, and the duration of infusion should be no less than 15 minutes. Risk factors for the deterioration of renal function include impaired baseline renal function and multiple cycles of bisphosphonate treatment.

Zometa is not recommended in patients with bone metastases with severe renal impairment. In patients with mild to moderate renal impairment at baseline, lower doses of Zometa are recommended based on calculated creatinine clearance. Before each Zometa dose, serum creatinine should be measured and treatment should be withheld for renal deterioration until serum creatinine has returned to within 10% of the baseline value.

Zometa should not be used during pregnancy. Women of childbearing potential should be advised to avoid becoming pregnant. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Osteonecrosis of the jaw (ONJ) has been reported predominantly in cancer patients treated with intravenous bisphosphonates, including Zometa. Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. Post-marketing experience and the literature suggest a greater frequency of reports of ONJ based on tumor type (advanced brea
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... Subjects with ALS, RICHMOND, Calif., Sept. 3 ... it has opened a Phase,2 clinical trial (SB-509-801) to ... degenerative motor-neuron disease for which there,are limited treatment options ... injectable formulation of a plasmid,encoding a zinc finger DNA-binding ...
... , - This Analysis Showed That Multaq(R) (Dronedarone) ... Atrial Fibrillation or Atrial Flutter,Already Adequately Treated by Antithrombotic ... the data from the ATHENA study,were presented today at ... Cardiology congress 2008, in Munich, Germany. Previous results,from the ...
Cached Medicine Technology:Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... Product liability lawsuits filed in the ... http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal court, ... in the U.S. District Court, Northern District of Ohio ... conference on January 7, 2015, at the Paul G. ... Palm Beach, Florida. The Conference is scheduled to begin ...
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... Overeating is common during the holidays, but there are strategies ... "Don,t arrive at a party hungry. It may seem ... attending a party, but deprivation leads to hunger, and hunger ... Hospital in Mount Kisco, N.Y., said in a hospital news ... and even to have a snack before attending a party ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... Smokerman Can,t because he smokes cigarettes... New anti-tobacco ads star a toy ... the health effects from his tobacco use. , ... Salt Lake City, ... Lake City today launched a new series of television ads starring a ...
... 11 The Grand Opening Celebration of Ocean,Blue ... from 7:00 until,10:00 p.m. Ocean Blue Plastic Surgery ... most prestigious addresses. Guests are invited to enjoy ... Plastic Surgery while,sampling hors d,oeuvres and sipping cocktails ...
... The Beryl Institute is seeking speakers,for its annual ... Worth,Metroplex. The theme for the conference is "The ... to improving customer service in,healthcare and will feature ... ways healthcare organizations can deliver,superior customer service., ...
... HealthCore, WellPoint,s health,outcomes research subsidiary, today presented ... in collaboration with the National Lipid Association,that ... American adults. The study,findings, presented during the ... Orleans, suggest that regardless of gains made ...
... General Nutrition Centers, Inc.,("GNC" the "Company" or "we"), ... reported its financial results for the third,quarter ended ... indirect wholly owned subsidiary of GNC Parent LLC,which ... ("Ares") and,Ontario Teachers, Pension Plan Board ("Teachers") through ...
... Before Holidays, WASHINGTON, Nov. 11 The American Red ... cards to service men,and women in the United States and ... the public is invited to send holiday,cards with their message ... Red Cross and Pitney Bowes will then screen cards for ...
Cached Medicine News:Health News:Anti-Tobacco Campaign Targets Twelve-and-Under Youth with Debut of "Smokerman" in New Television Ads 2Health News:Anti-Tobacco Campaign Targets Twelve-and-Under Youth with Debut of "Smokerman" in New Television Ads 3Health News:Ocean Blue Plastic Surgery to Open This Month on Brickell Avenue 2Health News:The Beryl Institute Announces Call for Speakers for 2009 Conference Dedicated to Healthcare Customer Service: 'The Pursuit of Excellence' 2Health News:Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications 2Health News:Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications 3Health News:Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications 4Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 2Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 3Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 4Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 5Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 6Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 7Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 8Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 9Health News:General Nutrition Centers, Inc. Reports Third Quarter 2008 Financial Results 10Health News:'Holiday Mail for Heroes' to Deliver One Million Cards to Service Members and Families 2Health News:'Holiday Mail for Heroes' to Deliver One Million Cards to Service Members and Families 3
Tilt Adapter for the 8000 Sliding Microtome to allow for orientation of the specimen....
... Microtome has a look that is revolutionary, a ... functions and capabilities that will please the most ... experience and knowledge but still breaking new ground ... will be the answer to many of your ...
Clock oil, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Medicine Products: